微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
RSS 官方收录 · 可信分层展示
关键摘要
The Food and Drug Administration on Friday approved a new treatment for a rare and slow-growing cancer that causes an overproduction of red blood cells.…
- The drug, called rusfertide, was developed by the biotech company Prot…
- It will be sold by Takeda, the Japanese pharma company, under the bran…
- Administered via a weekly injection, Mimrylo was cleared to treat poly…
摘要引擎：抽取
正文提要
The Food and Drug Administration on Friday approved a new treatment for a rare and slow-growing cancer that causes an overproduction of red blood cells.
The drug, called rusfertide, was developed by the biotech company Protagonist Therapeutics. It will be sold by Takeda, the Japanese pharma company, under the brand name Mimrylo.
Administered via a weekly injection, Mimrylo was cleared to treat polycythemia vera, a chronic blood cancer in which overproduction of red blood cells thickens a patient’s blood, resulting in higher risk for life-threatening heart attacks, strokes, and blood clots.